Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #clinicalstudy--Blade Therapeutics, Inc. today announced the successful completion of a phase 1 drug-drug interaction clinical study of cudetaxestat.

Click to view original post